^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
Drug class:
CLDN18.2-targeted CAR-T immunotherapy, Mesothelin-targeted CAR-T immunotherapy, HER2-targeted CAR-T immunotherapy, GUCY2C-targeted CAR-T immunotherapy, MUC1-targeted CAR-T immunotherapy, B7-H3-targeted CAR-T immunotherapy, EGFR-targeted CAR-T immunotherapy, GPC-3-targeted CAR-T immunotherapy, PSMA-targeted CAR-T immunotherapy, AXL-targeted CAR-T immunotherapy, Lewis Y antigen-targeted CAR-T immunotherapy, PSCA-targeted CAR-T immunotherapy, TGFβ-targeted CAR-T immunotherapy
Related drugs:
Phase 1
Second Affiliated Hospital of Guangzhou Medical...
Recruiting
Last update posted :
02/14/2023
Initiation :
07/01/2017
Primary completion :
08/01/2024
Completion :
08/01/2026
EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
|
MSLN expression • EGFR positive • GPC3 expression
|
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
Share
